Artificial intelligence, which is gradually integrated into every part of our lives, seems to be of critical importance for our health very soon. Because, scientists working within Genetika+, an Israel-based health technology company, started to develop personalized medicine with artificial intelligence.
Scientists began to produce brain cells with blood from the patient and then work on them. As part of the research, experts focusing on antidepressant drugs tried the effects of different drugs on brain cells. By processing all the findings they obtained into specially trained artificial intelligence, scientists were able to adjust the right drug and the right dosage. Speaking on the subject, Dr. Talia Cohen Solal says, “We can design the right drug for every patient, all at once.” He explained how effective the new method was.
It is slated to launch next year
The company, which is funded by the European Research Council of the European Union and the European Innovation Council, also cooperates with pharmaceutical companies. The technology, which is still under development, will be released as of next year if it can show sufficient success. Many experts believe such technology could rewrite the rules of the pharmaceutical industry. Moreover, the technology, which focuses only on antidepressants for now, can be customized for any disease in the coming years.
Meanwhile; Genetika+ is not the only company producing artificial intelligence-focused drugs. Studies on drugs developed using artificial intelligence models from all over the world continue. In fact, one of the drugs used in lung diseases has been in clinical testing for a while. Experts say that while a drug developed using traditional methods takes 4 years, artificial intelligence can handle it in as little as 18 months. In addition, the preference of artificial intelligence in drug production significantly reduces costs.
56044
